BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gulati S, Schoenhofen IC, Lindhout-Djukic T, Lewis LA, Moustafa IY, Saha S, Zheng B, Nowak N, Rice PA, Varki A, Ram S. Efficacy of Antigonococcal CMP-Nonulosonate Therapeutics Require Cathelicidins. J Infect Dis 2020;222:1641-50. [PMID: 32692363 DOI: 10.1093/infdis/jiaa438] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Jen FE, Ketterer MR, Semchenko EA, Day CJ, Seib KL, Apicella MA, Jennings MP. The Lst Sialyltransferase of Neisseria gonorrhoeae Can Transfer Keto-Deoxyoctanoate as the Terminal Sugar of Lipooligosaccharide: a Glyco-Achilles Heel That Provides a New Strategy for Vaccines to Prevent Gonorrhea. mBio 2021;12:e03666-20. [PMID: 33758087 DOI: 10.1128/mBio.03666-20] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Lim KYL, Mullally CA, Haese EC, Kibble EA, McCluskey NR, Mikucki EC, Thai VC, Stubbs KA, Sarkar-Tyson M, Kahler CM. Anti-Virulence Therapeutic Approaches for Neisseria gonorrhoeae. Antibiotics (Basel) 2021;10:103. [PMID: 33494538 DOI: 10.3390/antibiotics10020103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Shafer WM. Drug Targeting a Gonococcal Virulence Factor Exploits Host Antimicrobial Peptides in Clearance of Infection. J Infect Dis 2020;222:1585-6. [PMID: 32692362 DOI: 10.1093/infdis/jiaa439] [Reference Citation Analysis]
4 Lin EY, Adamson PC, Klausner JD. Epidemiology, Treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: Current Strategies and Future Directions. Drugs 2021;81:1153-69. [PMID: 34097283 DOI: 10.1007/s40265-021-01530-0] [Cited by in F6Publishing: 2] [Reference Citation Analysis]